ID,Title,Authors,Source,Journal,Database,Type,Language,Publication year,Descriptor(s),Keyword(s),Publication Country,Fulltext URL, Abstract,Entry Date,Volume number,Issue number,DOI,ISSN,Accession number,PMCID
"biblio-1393925","Update on the diagnosis and management of neurocysticercosis/ Atualização no diagnóstico e manejo da neurocisticercose","Takayanagui, Osvaldo Massaiti; Haes, Tissiana Marques de","Arq. neuropsiquiatr;Arq. neuropsiquiatr;80(5,supl.1): 296-306, May 2022. graf","Arq. neuropsiquiatr","LILACS","article","en","2022","","Albendazol; Albendazole; Cerebrospinal Fluid; Cisticercose; Cysticercosis; Epilepsia; Epilepsy; Imageamento por Ressonância Magnética; Líquido Cefalorraquiano; Magnetic Resonance Imaging; Praziquantel; Praziquantel; Taenia solium; Taenia solium","BR","http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2022000700296","ABSTRACT  Background:  Neurocysticercosis (NCC) is a serious public health problem in several developing countries, including those in Latin America, Asia, and Africa. NCC is considered to be the main cause of late-onset epilepsy in endemic areas.  Objective:  This review summarizes recent advances in diagnosis and therapy of NCC. Methods: Relevant articles and books were reviewed and used as a source of information for this review.  Results:  The diagnosis of NCC is based upon neuroimaging studies (MRI and computed tomography) and laboratory analysis of the cerebrospinal fluid (CSF). Praziquantel and albendazole are considered parasiticidal drugs against NCC, but there is an intense debate over the value and safety of these drugs.  Conclusion:  Given the relative scarcity of clinical trials, more comparative interventional studies, especially randomized controlled trials in long-term clinical evolution, are required in order to clarify the controversy over the validity of parasitic therapy in patients with NCC.",20220916,80,5,supl.1,10.1590/0004-282x-anp-2022-s115,0004-282X,,
"lil-688526","Neurocysticercosis/ Neurocisticercose","Takayanagui, Osvaldo M.","Arq. neuropsiquiatr;Arq. neuropsiquiatr;71(9B): 710-713, set. 2013.","Arq. neuropsiquiatr","LILACS","article","en","2013","Humanos; Neurocisticercose; Albendazol/uso terapêutico; Anti-Helmínticos/uso terapêutico; Neurocisticercose/líquido cefalorraquidiano; Neurocisticercose/diagnóstico; Neurocisticercose/terapia; Praziquantel/uso terapêutico","Albendazol; Albendazole; Cisticercose; Cysticercosis; Epilepsia; Epilepsy; Praziquantel; Taenia solium","BR","http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2013001000710","Cysticercosis is one of the most common parasitic diseases of the nervous system in humans, and constitutes a major public health problem for most of the developing world. The clinical manifestations of neurocysticercosis (NCC) largely depend on the the host immune response against the parasite. NCC diagnosis is based upon neuroimaging studies (computerized tomography, magnetic resonance imaging) and antibody/antigen detection in the serum and the cerebrospinal fluid. Anticysticercal therapy has been marked by an intense controversy. Randomized controlled trials evaluating the clinical benefit of treatment have yield conflicting data with some studies indicating a benefit and others failing to show a difference. Prevention strategies must rely on multiple approaches, tailoring each to the special features of the particular endemic area.",20131018,71,9B,10.1590/S0004-282X2013001000710,0004-282X,,
"lil-590600","Estudio comparativo de prazicuantel frente a albendazol en el tratamiento de neurocisticercosis infantil: servicio clinica pediatrica, Hospital Rebagliati - 2003/ Comparative study of prazicuantel against albendazol in the treatment of infantile neurocysticercosis: pediatric clinical service, Hospital Rebagliati - 2003","Huanca Payehuanca, David Justo","Lima; s.n; 2010. 48 p. ilus, tab.","","LILACS","thesis","es","2010","Humanos; Masculino; Feminino; Pré-Escolar; Criança; Albendazol/uso terapêutico; Neurocisticercose/tratamento farmacológico; Criança; Praziquantel/uso terapêutico","","PE","","Entre julio del 2003 y junio del 2009 en el Servicio de Clínica Pediátrica del Hospital E. Rebagliati M. fueron hospitalizados 31 pacientes que reunían criterios clínicos y radiográficos compatibles con neurocisticercosis. Aplicando los criterios de inclusión y exclusión, la muestra final estuvo constituida por 25 niños de los cuales 8 fueron hombres y 17 mujeres. Trece pacientes recibieron tratamiento con albendazol (5 niños y 8 niñas) y doce pacientes recibieron prazicuantel (3 niños y 9 niñas). En el presente estudio el tratamiento con prazicuantel en un solo día fue tan efectivo como el tratamiento con albendazol por siete días. La administración de prazicuantel fue bien tolerado por los niños. Sólo uno de ellos presentó dolor de cabeza que remitió luego de la administración de dexametasona.",20110401,,,,,,
